Ni Guoying, Wang Tianfang, Yang Lin, Wang Yuejian, Liu Xiaosong, Wei Ming Q
a School of Medical Science and Griffith Health Institute, Griffith University , Gold Coast , QLD , Australia.
d Tangshan Supervision Institute of Health , Tangshan , China.
Hum Vaccin Immunother. 2016 Mar 3;12(3):599-606. doi: 10.1080/21645515.2015.1089008.
Late stage solid tumors cause significant cancer mortality rates worldwide and effective therapy remains a big challenge. Cancer therapeutic vaccines elicit tumor specific T cells that kill tumor cells yet often fail to result in tumor destruction because of the limited T cell response and the local immune-suppressive environment. Blocking interleukin 10 (IL-10) signaling at the time of therapeutic vaccination elicits much stronger T cell responses than vaccination without IL-10 blocking. Anaerobic oncolytic bacteria target hypoxic regions of the late stage tumor tissues which not only stops tumor growth but also provides a pro-inflammatory environment that may increase the effectiveness of a therapeutic vaccine by recruiting more effector T cells to tumor site. In this review, we argue that combining both bacterial and vaccine therapies may improve the efficiency of late stage cancer management.
晚期实体瘤在全球范围内导致了显著的癌症死亡率，有效的治疗仍然是一个巨大的挑战。癌症治疗性疫苗可引发肿瘤特异性T细胞来杀死肿瘤细胞，但由于T细胞反应有限以及局部免疫抑制环境，往往无法导致肿瘤被破坏。在治疗性疫苗接种时阻断白细胞介素10（IL-10）信号会引发比不阻断IL-10的疫苗接种更强的T细胞反应。厌氧溶瘤细菌靶向晚期肿瘤组织的缺氧区域，这不仅能阻止肿瘤生长，还能提供一个促炎环境，可能通过招募更多效应T细胞到肿瘤部位来提高治疗性疫苗的有效性。在这篇综述中，我们认为将细菌疗法和疫苗疗法相结合可能会提高晚期癌症治疗的效率。
